Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.46 |
| ▸ | RHOC | P08134 | 1/20 | 0.45 |
| ▸ | RHOA | P61586 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255658 | 0.83 | FFAR1 (0.50) | FFAR1FFAR4PPARATHRATHRB | |
| SCHEMBL5939432 | 0.81 | RHOC (0.59) | FFAR1FFAR4RHOCRHOAKDM4E | |
| SCHEMBL18252816 | 0.80 | FFAR1 (0.47) | FFAR1FFAR4PPARATHRATHRB | |
| SCHEMBL1015795 | 0.79 | LMNA (0.54) | FFAR1FFAR4THRATHRBLMNA | |
| SCHEMBL21346465 | 0.77 | FFAR1 (0.45) | FFAR1FFAR4PPARATHRATHRB | |
| SCHEMBL13536889 | 0.76 | S1PR1 (0.66) | FFAR1FFAR4S1PR1S1PR3S1PR2 | |
| SCHEMBL30151169 | 0.75 | FFAR4 (0.48) | FFAR1FFAR4PPARATHRATHRB | |
| SCHEMBL16033358 | 0.75 | TACR1 (0.50) | FFAR1FFAR4RHOCRHOALMNA | |
| SCHEMBL17310946 | 0.73 | RXRA (0.51) | FFAR1FFAR4THRATHRBLMNA | |
| SCHEMBL30151135 | 0.72 | THRA (0.47) | FFAR1FFAR4PPARATHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023075-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023075-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | FFAR1 563/4885FFAR4 747/4885RHOC 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.